Some people do not respond to treatment* with standard antidepressant drugs. Their symptoms may have diminished in intensity, but they still linger on. Patients have tried one conventional medication after another, to no avail. Even while taking two medications at once to manage their persistent symptoms, they still suffer from potential fatigue, insomnia, sadness and feelings of hopelessness2.
If this situation sounds familiar, speak with your doctor about Marplan® (isocarboxazid) Tablets as an alternative for your depression symptoms. Unlike conventional antidepressants, Marplan® (isocarboxazid) Tablets works differently than other treatments for Major Depression3. Marplan® (isocarboxazid) Tablets is a MAO Inhibitor (a drug that blocks the enzyme mono-amine-oxydase) and this mode of action enables Marplan® (isocarboxazid) Tablets to raise the levels of all three of the 'chemical messengers' (otherwise known as neurotransmitters) in the brain that can elevate mood3. Other antidepressants only elevate the levels of two of these three chemical messengers3.
Marplan® (isocarboxazid) Tablets' effectiveness can be attributed to its ability to raise the levels of all three neurotransmitters; that may be the reason Marplan® (isocarboxazid) Tablets is so effective in patients who have failed to respond to prior medications3. Marplan® (isocarboxazid) Tablets' could provide the symptom control you need.
In this website are helpful resources on Treatment-Resistant* Major Depression and a downloadable guide to discuss your questions with your doctor.
- Why doctors recognize that treatment-resistant* major depression is different from other forms of depression (and more challenging to treat).
- Why Marplan® (isocarboxazid) Tablets' different mode of action may often alleviate symptoms of depression that are treatment-resistant3*.
- A few simple rules that should be followed to optimize your therapy and take this potent medication safely.
Please see Medication Guide for useful information for patients taking Marplan® (isocarboxazid) Tablets.
*Treatment failure with first-line antidepressants.
Please see Full Prescribing Information including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO Inhibitors are contraindicated with certain drugs. Potential hypertensive crises may occur with foods that contain tyramine. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan® (isocarboxazid) Tablets or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan® (isocarboxazid) Tablets is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use).
Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.